Epigenetic Reprogramming of the Tumor Microenvironment: An Evidence-Graded Framework from Cell States to Clinical Translation

Purpose of Review The tumor microenvironment (TME) is a dynamic multicellular system in which malignant, immune, stromal, vascular, and metabolic compartments adapt to spatial and therapeutic pressure. Epigenetic regulation can stabilize these adaptations without changing DNA sequence, but evidence varies. Transcriptomic heterogeneity alone does not establish epigenetic reprogramming; direct chromatin measurement and causal perturbation are needed to distinguish targetable mechanisms from associated cell states. We assess how directly epigenetic evidence supports claims across TME compartments and where clinical extrapolation remains uncertain. Recent Findings This critical narrative review evaluates an evidence chain linking a regulator to a directly measured chromatin alteration, a defined cellular state, an intercellular consequence, and a context-specific therapeutic outcome. Evidence is graded from transcriptional association through epigenomic measurement and functional perturbation to patient validation and clinical outcomes. The review considers malignant, lymphoid, myeloid, fibroblast, endothelial, spatial, metabolic, and therapeutic contexts, while distinguishing epigenetic mechanisms from environmental inputs and measurement technologies. It asks separately whether treatment engages its proposed target, changes the relevant chromatin state, affects neighboring compartments, and improves patient outcomes. Summary Translation requires compartment-resolved pharmacodynamic assays, biologically informed dosing and sequencing, prospective biomarkers, and trials linking defined epigenetic state changes to meaningful patient benefit. Clinical studies should stratify by disease and cell compartment, report pharmacodynamic evidence, and avoid treating early response as proof of broad utility.

Authors

Institutions

Publication Details

Journal
Current Tissue Microenvironment Reports
Published
2026-11-18
DOI
https://doi.org/10.1007/s43152-026-00074-3
Primary Topic
Epigenetics and DNA Methylation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Epigenetic Reprogramming of the Tumor Microenvironment: An Evidence-Graded Framework from Cell States to Clinical Translation

Udayan Bhattacharya
Current Tissue Microenvironment Reports
Epigenetics and DNA Methylation
article

Epigenetic Reprogramming of the Tumor Microenvironment: An Evidence-Graded Framework from Cell States to Clinical Translation

Udayan Bhattacharya
article en

Abstract

Purpose of Review The tumor microenvironment (TME) is a dynamic multicellular system in which malignant, immune, stromal, vascular, and metabolic compartments adapt to spatial and therapeutic pressure. Epigenetic regulation can stabilize these adaptations without changing DNA sequence, but evidence varies. Transcriptomic heterogeneity alone does not establish epigenetic reprogramming; direct chromatin measurement and causal perturbation are needed to distinguish targetable mechanisms from associated cell states. We assess how directly epigenetic evidence supports claims across TME compartments and where clinical extrapolation remains uncertain. Recent Findings This critical narrative review evaluates an evidence chain linking a regulator to a directly measured chromatin alteration, a defined cellular state, an intercellular consequence, and a context-specific therapeutic outcome. Evidence is graded from transcriptional association through epigenomic measurement and functional perturbation to patient validation and clinical outcomes. The review considers malignant, lymphoid, myeloid, fibroblast, endothelial, spatial, metabolic, and therapeutic contexts, while distinguishing epigenetic mechanisms from environmental inputs and measurement technologies. It asks separately whether treatment engages its proposed target, changes the relevant chromatin state, affects neighboring compartments, and improves patient outcomes. Summary Translation requires compartment-resolved pharmacodynamic assays, biologically informed dosing and sequencing, prospective biomarkers, and trials linking defined epigenetic state changes to meaningful patient benefit. Clinical studies should stratify by disease and cell compartment, report pharmacodynamic evidence, and avoid treating early response as proof of broad utility.

Current Tissue Microenvironment ReportsVol. 7(1)
University of Michigan (US), Michigan Medicine (US)
Good health and well-being
Epigenetics and DNA Methylation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon